Reprogramming of Tumor Stroma to Enhance Cancer Immunotherapy

Informacje na temat projektu

REACT

Identyfikator umowy o grant: 101158040

DOI

10.3030/101158040

Projekt został zamknięty

Data podpisania przez KE 12 Marca 2024

Data rozpoczęcia 1 Czerwca 2024

Data zakończenia 30 Listopada 2025

Finansowanie w ramach

• European Research Council (ERC)

Koszt całkowity

Brak danych

Wkład UE

€ 150 000,00

Koordynowany przez

INSTITUT PASTEUR
France

Periodic Reporting for period 1 - REACT (Reprogramming of Tumor Stroma to Enhance Cancer Immunotherapy)

Okres sprawozdawczy: 2024-06-01 do 2025-11-30

Podsumowanie kontekstu i ogólnych celów projektu

Immunotherapies such as immune checkpoint inhibitors (ICIs) and CAR T cells can induce durable responses in some cancers, yet their efficacy in solid tumors remains limited. A major driver of resistance is the hostile tumor microenvironment (TME), which restricts effector immune-cell infiltration or can suppress their function even after they reach the tumor. Although several combination strategies have been developed to boost immunotherapy activity, many are associated with substantial toxicity, underscoring the need for new approaches that selectively target TME components that shape anti-tumor immunity.

Building on our ERC Consolidator Grant project, the overall objectives of this proposal were to develop novel therapeutic strategies targeting structural components of the TME and evaluate combination regimens designed to enhance the efficacy of immunotherapies in solid tumors.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

During this project, we characterized therapeutic agents targeting the TME of solid tumors in collaboration with industrial partners. Our key achievements were the identification of lead agent candidates that induced anti-tumor activity in vivo, together with the optimization of a window for co-treatment when combined with current standard therapies. In parallel, we initiated collaborations with experts to expand the translational aspects of these efforts

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

We identified novel therapeutic agents to improve the treatment of solid tumors. These findings have generated renewed interest from potential investors and industrial partners to further advance this concept and, potentially, extend it to additional mechanisms of resistance in solid tumors, opening new avenues for research and therapeutic development.